Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 155-163

  Macdonald, A Graham ^a,b   Keyes, Mira ^a   Kruk, Alexandrea ^a   Duncan, Graeme ^a   Moravan, Veronika ^a   Morris, W James ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Brachytherapy; Erectile dysfunction; Penile bulb; Prostate carcinoma

Indexed keywords

CARCINOGENS; HORMONES; MEDICAL PROBLEMS; PATIENT TREATMENT; REGRESSION ANALYSIS; TUMORS;

BRACHYTHERAPY; ERECTILE DYSFUNCTION; PENILE BULB; PROSTATE CARCINOMA;

ONCOLOGY;

DEXAMETHASONE; HORMONE; PYRAZINAMIDE; TERAZOSIN; TESTOSTERONE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DOSIMETRY; DRUG POTENCY; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; TRANSRECTAL ULTRASONOGRAPHY; ANALYSIS OF VARIANCE; IMPOTENCE; MIDDLE AGED; OBSERVER VARIATION; PENIS; PENIS ERECTION; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIATION EXPOSURE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; HUMANS; IMPOTENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OBSERVER VARIATION; PENILE ERECTION; PENIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 26944465026     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.12.056     Document Type: Article

References (31)

1. BC Cancer Agency. Crude cancer rates - incidence. Available at: www.bccancer.bc.ca/HPI/CancerStatistics/FF/Rates/Inc/ default.htm. Website accessed June 30, 2004.
2. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-1068.
3. Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893-902.
4. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
5. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998;159:1988-1992.
6. Tierney LM, MacPhee SJ, Papadakis MA, eds. Current medical diagnosis and treatment. 43rd ed. New York: Lange Medical Books/McGraw-Hill; 2004.
7. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
8. Bradley KA, Chappell R, Yuan Z, et al. Erectile dysfunction and prostate brachytherapy doses to the penile bulb and neurovascular bundles [abstract]. Int J Radiat Oncol Biol Phys 2003;57(Suppl.):S399-S400.
9. DiBiase SJ, Wallner K, Tralins K, et al. Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys 2000;46:1301-1307.
10. Merrick GS, Butler WM, Dorsey AT, et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2000;48:1069-1074.
11. Merrick GS, Wallner K, Butler WM, et al. Short-term sexual function after prostate brachytherapy. Int J Cancer 2001;96: 313-319.
12. Merrick GS, Wallner K, Butler WM, et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001;50:597-604.
13. Fisch BM, Pickett B, Weinberg V, et al. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001;57:955-959.
14. Pickett B, Fisch BM, Weinberg V, et al. Dose to the bulb of the penis is associated with the risk of impotence following radiotherapy for prostate cancer [Abstract]. Int J Radiat Oncol Biol Phys 1999;45(Suppl.):263.
15. Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54: 462-470.
16. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94.
17. Keyes M, Pickles T, Agranovich A, et al. 125-I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;60:40-50.
18. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001;165:436-439.
19. Wallner KE, Merrick GS, Benson ML, et al. Penile bulb imaging. Int J Radiat Oncol Biol Phys 2002;53:928-933.
20. Merrick GS, Butler WM, Wallner KE, et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002;54:1055-1062.
21. Kiteley RA, Lee WR, deGuzman AF, et al. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002;1:90-94.
22. Merrick GS, Butler WM. The dosimetry of brachytherapy-induced erectile dysfunction. Med Dosim 2003;28:271-274.
23. Wright JL, Newhouse JH, Laguna JL, et al. Localization of neurovascular bundles on pelvic CT and evaluation of radiation dose to structures putatively involved in erectile dysfunction after prostate brachy therapy. Int J Radiat Oncol Biol Phys 2004;59:426-435.
24. Selek U, Cheung R, Lu M, et al. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation. Int J Radiat Oncol Biol Phys 2004;59:1039-1046.
25. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997;158:1408-1410.
26. Ghilezan M, Vargas C, Gustafson G, et al. Erectile dysfunction (ED) after prostate cancer brachytherapy as sole treatment modality. The William Beaumont Hopsital's experience with HDR vs. LDR (Pd103 permanent implants) [Abstract]. Radiother Oncol 2004;71(Suppl.):S56.
27. Schellenberg D, Keyes M, Bucci J, et al. Decreased incidence of urinary retention after prostate brachytherapy: The effect of the learning curve? [Abstract]. Radiother Oncol 2004;71(Suppl.): S55-56.
28. Mulhall JP, Yonover P, Sethi A, et al. Radiation exposure to the corporeal bodies during 3-dimensional conformal radiation therapy for prostate cancer. J Urol 2002;167:539-542.
29. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998;40:129-133.
30. Mulhall JP, Yonover PM. Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy for prostate cancer [Letter]. Urology 2001;58:828.
31. Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54: 462-470.